Beset by accounting woes Immucor faces shareholder class action
This article was originally published in Clinica
After what has been described as "a month of bad news", blood screening technology firm Immucor is now facing the inevitable onslaught of lawsuits from unhappy shareholders.
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.